Cancer Research Funding In Austria: How Much Is Invested?

Cancer research is vital to helping ease the global burden of the disease. While the US is the biggest funder of cancer research, Austria is at the forefront of the fight against cancer in Europe. Researchers and oncologists throughout Austria are working together to develop and commercialise diagnostics and treatments. Collaboration across multiple disciplines is integral to modern cancer treatment.

Cancer research funding in Austria

Austria is at the forefront of the fight against cancer in Europe and plays an important part with several pioneering initiatives. The country's small size and strong networks facilitate the formation of multidisciplinary teams that are needed to tackle cancer. Researchers and oncologists throughout Austria collaborate across multiple disciplines to develop and commercialise diagnostics and treatments, bringing together industry, healthcare and primary research.

Universities and research institutions, as well as companies, are very active in the field of cancer research in Austria. Oncology is the most intensively researched field in the country in terms of clinical studies, accounting for about one-third of all studies. In 2021, researchers at the Medical University of Vienna and Vienna General Hospital published the first worldwide personalised medicine study using a functional test to demonstrate the clinical feasibility and efficacy of individualised therapy for lymphoma and leukaemia.

In addition to cancer research funding, Austria is also investing heavily in the development of quantum technologies. Initiatives such as Quantum Austria, featuring €107 million in investments, are strengthening the country's quantum technology ecosystem and contributing to its leading role as a business location for innovative companies and investors in this field.

Cancer treatment costs in Austria

Austria is a leader in cancer research and treatment in Europe. The country's small size and strong networks facilitate multidisciplinary collaboration, which is integral to modern cancer treatment. Researchers and oncologists work together to develop and commercialise innovative immunotherapy, novel molecular targets, and gene therapy. This collaborative approach brings together industry, healthcare, and primary research, driving advancements in cancer diagnostics and therapies.

One example of cost variation in cancer treatment modalities is seen in prostate cancer, the most common cancer in men. In Austria, external beam radiotherapy, particularly ultrahypofractionated radiotherapy, is the least expensive treatment option for low-risk prostate cancer, costing 2,492 € per treatment. Surgery and other forms of radiotherapy may incur different costs, but an economic comparison of these treatments in Austria has not yet been conducted.

Cancer drug research and development is a significant expense worldwide, with an estimated US$307 billion expected to be spent in this area by 2026. While it is unclear how much of this investment will be directed towards Austria, the country's commitment to cancer research and collaboration positions it as a key contributor to advancements in cancer treatment.

Overall, cancer treatment costs in Austria are influenced by various factors, including the type of cancer, the chosen treatment modality, and the country's involvement in cancer research and innovation. While specific data on overall costs may not be readily available, Austria's leadership in cancer research and its focus on multidisciplinary collaboration suggest that treatment expenses are a critical consideration in the country's approach to cancer care.

Cancer research initiatives in Austria

Austria is at the forefront of the fight against cancer in Europe, with several pioneering initiatives. The country's small size and strong networks make it well-suited to forming the multidisciplinary teams needed to tackle cancer. Researchers and oncologists throughout Austria are working together to develop and commercialise diagnostics and treatments, including innovative immunotherapy, novel molecular targets and gene therapy. Collaboration across multiple disciplines is integral to modern cancer treatment, and Austrian cancer research brings together industry, healthcare and primary research.

An example of an economic analysis of cancer treatment in Austria is a study comparing the costs of radiotherapy and surgery for prostate cancer. The study found that external beam radiotherapy, especially ultrahypofractionated, is the least costly treatment modality for low-risk prostate cancer, with costs of €2,492 per treatment.

Cancer research funding globally

The US is the biggest funder of cancer research, providing 57.3% of the total cancer research funding awarded between 2016 and 2020. While most of the world's biggest funders are transparent about their funding decisions, the distribution of research money doesn't always match the needs on the ground.

By 2026, an estimated US$307 billion is expected to be spent on cancer-drug research and development worldwide, with 55% of this focused on just four types of cancer: breast, lung, prostate, and multiple myeloma (blood cancer).

Austria, a small country with strong networks, is at the forefront of cancer research in Europe. Multidisciplinary teams of researchers and oncologists collaborate across multiple disciplines to develop and commercialise diagnostics and treatments, including innovative immunotherapy, novel molecular targets, and gene therapy.

Cancer drug research and development

Austria recognises the importance of collaboration across multiple disciplines in modern cancer treatment. Multidisciplinary research networks bring together industry, healthcare, and primary research to accelerate progress in cancer drug research and development. This integrated approach enables the efficient translation of research findings into clinical practice, ultimately benefiting patients.

While specific figures on Austria's spending on cancer research are not readily available, the country's commitment to cancer drug research and development is evident. Austria prioritises economic evaluations of cancer treatments, as demonstrated by a study comparing the costs of radiotherapy and surgery for prostate cancer in Vienna and Austria. This study, based on data from the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection, provides valuable insights into the economic considerations of cancer treatment options.

By 2026, it is estimated that a significant portion of the US$307 billion spent globally on cancer-drug research and development will be allocated to four key areas: breast, lung, prostate, and multiple myeloma (blood cancer). Austria's contributions to cancer drug research and development are expected to play a role in advancing our understanding and treatment of these cancer types.

Frequently asked questions